

RECTAL
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE: SATURDAY, APRIL 30th, 2016

TIME: 09:15 – 10:00

CHAIRS: DR. HAGEN KENNECKE & DR. REBECCA AUER

09:15 WELCOME AND INTRODUCTION **DR. H. KENNECKE / DR. R. AUER**

09:20 ACTIVE TRIALS FOR UPDATE/DISCUSSION

CRC.7 (NCCTG N1048- PROSPECT): A PHASE II/III TRIAL OF NEOADJUVANT FOLFOX, WITH SELECTIVE USE OF COMBINED MODALITY CHEMORADIATION VERSUS PREOPERATIVE COMBINED MODALITY CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER PATIENTS UNDERGOING LOW ANTERIOR RESECTION WITH TOTAL MESORECTAL EXCISION **DR. H. KENNECKE**

09:25 APPROVED TRIALS IN DEVELOPMENT

CO.28: PHASE II: NON-OPERATIVE MANAGEMENT OF CT1-3 NO LOW RECTAL CANCER **DR. C. BROWN/DR. H. KENNECKE**

09:40 TRIAL CONCEPTS IN DEVELOPMENT

A SINGLE ARM PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL **DR. E. CHEN**

CREATE: CHEMOTHERAPY FOR RECTAL CANCER BEFORE OR AFTER LOCAL TREATMENT **DR. H. KENNECKE**

9:55 INTERGROUP TASK FORCE UPDATE

TNT (NRG GI-002): A PHASE II CLINICAL TRIAL PLATFORM OF SENSITIZATION UTILIZING TOTAL NEOADJUVANT THERAPY (TNT) IN RECTAL CANCER **DR. H. KENNECKE**

10:00 CLOSING REMARKS